Kimi S Vesta1, Shaunta' D Martina, Ellen A Kozlowski. 1. Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK 73190-5040, USA. Kimi-Vesta@ouhsc.edu
Abstract
OBJECTIVE: To report a case of propofol-induced priapism. CASE SUMMARY: A 17-year-old male receiving propofol for induction of anesthesia during a cardiac ablation procedure developed priapism that required medical intervention and discontinuation of propofol. The priapism developed after a total propofol dose of 550 mg, lasted for 2 hours, and resolved immediately following medical intervention. The following day, the patient underwent a transesophageal echocardiogram and received a total propofol dose of 40 mg throughout the procedure. He again developed priapism, which resolved within one hour without medical intervention. DISCUSSION: Priapism experienced by this patient is considered to be drug-induced because of the temporal relationship, recurrence with rechallenge, and dose-response relationship. Using the Naranjo probability scale, we determined that propofol was a highly probable causative agent of priapism in this patient. CONCLUSIONS: Although, as of April 4, 2006, this adverse effect has not been previously reported, there is a strong correlation of propofol to priapism in this patient. Clinicians should be aware of this adverse effect.
OBJECTIVE: To report a case of propofol-induced priapism. CASE SUMMARY: A 17-year-old male receiving propofol for induction of anesthesia during a cardiac ablation procedure developed priapism that required medical intervention and discontinuation of propofol. The priapism developed after a total propofol dose of 550 mg, lasted for 2 hours, and resolved immediately following medical intervention. The following day, the patient underwent a transesophageal echocardiogram and received a total propofol dose of 40 mg throughout the procedure. He again developed priapism, which resolved within one hour without medical intervention. DISCUSSION: Priapism experienced by this patient is considered to be drug-induced because of the temporal relationship, recurrence with rechallenge, and dose-response relationship. Using the Naranjo probability scale, we determined that propofol was a highly probable causative agent of priapism in this patient. CONCLUSIONS: Although, as of April 4, 2006, this adverse effect has not been previously reported, there is a strong correlation of propofol to priapism in this patient. Clinicians should be aware of this adverse effect.
Authors: Antonio Francesco Maria Giuliano; Marco Vulpi; Francesca Passerini; Antonio Vavallo; Anna Belfiore; Saverio Forte; Vincenzo Ostilio Palmieri; Pasquale Ditonno Journal: Case Rep Urol Date: 2021-07-03
Authors: Myriam Lamamri; Ala Chebbi; Jordan Mamane; Sofia Abbad; Milena Munuzzolini; Florence Sarfati; Stéphane Legriel Journal: Am J Emerg Med Date: 2020-06-18 Impact factor: 2.469